. 2014 Dec 15;19(12):21085–21112. doi: 10.3390/molecules191221085

Table 2.

Resistance and cross-resistance profile of CBAs of in vitro generated CBA-resistant HIV-1 strains.

CBAs	NL4.3^2G12res	IIIB^2G12res	IIIB^HHAres	IIIB^GNAres	IIIB^AHres	IIIB^CV−Nres	NL4.3^CV−Nres	NL4.3^MVNres	IIIB^BanLecres	IIIB^GRFTres	IIIB^UDAres
AH	N.D. ^a	N.D.	N.D.	N.D.	19 ^b	N.D.	N.D.	N.D.	>66	118	N.D.
MVN	2	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	>100	N.D.	4	N.D.
2G12 mAb	>50	>36	>15	>15	>25	>45	>45	>38	>25	>35	>29
HHA	12	2	919	490	1	17	4	3	3	5	117
GNA	6	1	926	581	N.D.	23	1	2	N.D.	N.D.	39
BanLec	1	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	5	24	13	N.D.
GRFT	10	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	14	>106	>1900	N.D.
CV-N	1	3	29	11	N.D.	20	7	4	N.D.	N.D.	83
OAA	3	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	2	2	2	N.D.
UDA	8	N.D.	N.D.	N.D.	1	1	3	3	1	3	24

Notes: ^a: N.D. Not determined; ^b: Legend fold resistance: the indicated colors describe the antiviral activity [more- (shown in blue) or less active (shown in green-yellow-orange and red)] of various CBAs against different in vitro generated CBA-resistant HIV-1 strains.

Increased sensitivity

1 (none)

≥2–9 (low)

≥10–24 (moderate)

≥25–49 (high)

≥50 (very high)